Literature DB >> 10615228

How do doctors explain randomised clinical trials to their patients?

V A Jenkins1, L J Fallowfield, A Souhami, M Sawtell.   

Abstract

As part of a larger study designed to improve doctor-patient communication in randomised clinical trials (RCT), we audiotaped the discussions between doctor and patient in which consent was being obtained for a RCT. This paper reports on 82 discussions conducted by 5 clinical oncologists in both District General and University Hospital outpatient departments. When introducing the subject of trials, uncertainty about treatment decisions was expressed by the doctors in the majority of cases (79, 96.3%). This was most often stated in a general sense (78, 95.1%), but some mentioned personal uncertainty (12, 14.6%), an approach which helps to maintain a trusting doctor-patient relationship. The word randomization was mentioned in 51 (62.2%) consultations, although the process itself was usually described implicitly (78, 95.1%), e.g. by telling the patient that they would be allocated either one or other treatment. Analogies were used in 28 (34.1%) cases to describe the randomisation process. In addition, although treatments and side-effects were described frequently, (68, 82.9%) and (72, 87.8%) respectively, information leaflets about the trials were not given to 23 (28%) patients. The study shows that U.K. clinicians adopt individual methods when providing information and eliciting consent to trials.

Entities:  

Mesh:

Year:  1999        PMID: 10615228     DOI: 10.1016/s0959-8049(99)00116-1

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  34 in total

1.  Satisfaction with the decision to participate in cancer clinical trials is high, but understanding is a problem.

Authors:  M Jefford; L Mileshkin; J Matthews; H Raunow; C O'Kane; T Cavicchiolo; H Brasier; M Anderson; J Reynolds
Journal:  Support Care Cancer       Date:  2010-02-23       Impact factor: 3.603

2.  Genetic counseling communication with an African American BRCA1 kindred.

Authors:  Lee Ellington; Amiee Maxwel; Bonnie J Baty; Debra Roter; William N Dudley; Anita Y Kinney
Journal:  Soc Sci Med       Date:  2006-11-01       Impact factor: 4.634

3.  An examination of adherence strategies and challenges in poison control communication.

Authors:  Lee Ellington; Lisa Kennedy Sheldon; Sonia Matwin; Jackie A Smith; Mollie Merkley Poynton; Barbara Insley Crouch; E Martin Caravati
Journal:  J Emerg Nurs       Date:  2008-06-27       Impact factor: 1.836

4.  The obligation to participate in biomedical research.

Authors:  G Owen Schaefer; Ezekiel J Emanuel; Alan Wertheimer
Journal:  JAMA       Date:  2009-07-01       Impact factor: 56.272

5.  The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies.

Authors:  Joseph M Unger; Elise Cook; Eric Tai; Archie Bleyer
Journal:  Am Soc Clin Oncol Educ Book       Date:  2016

6.  Oncologists' recommendations of clinical trial participation to patients.

Authors:  Susan Eggly; Terrance L Albrecht; Felicity W K Harper; Tanina Foster; Melissa M Franks; John C Ruckdeschel
Journal:  Patient Educ Couns       Date:  2007-11-05

7.  Improving informed consent: pilot of a decision aid for women invited to participate in a breast cancer prevention trial (IBIS-II DCIS).

Authors:  I Juraskova; P Butow; A Lopez; M Seccombe; A Coates; F Boyle; N McCarthy; L Reaby; J F Forbes
Journal:  Health Expect       Date:  2008-09       Impact factor: 3.377

8.  Completion of the audit cycle: standardised nurse-led information for patients.

Authors:  R A Sharma; L Furber; L D Granger; C Archdeacon; G Thomas; R P Symonds
Journal:  Postgrad Med J       Date:  2003-11       Impact factor: 2.401

9.  Reasons for participating in randomised controlled trials: conditional altruism and considerations for self.

Authors:  Sharon K McCann; Marion K Campbell; Vikki A Entwistle
Journal:  Trials       Date:  2010-03-22       Impact factor: 2.279

10.  Performance-based readability testing of participant information for a Phase 3 IVF trial.

Authors:  Peter Knapp; D K Raynor; Jonathan Silcock; Brian Parkinson
Journal:  Trials       Date:  2009-09-01       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.